Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Smoldering Multiple Myeloma 1 Multiple Myeloma 1

Interventions

Dexamethasone 338 Bortezomib 188 Lenalidomide 186 Cyclophosphamide 166 Melphalan 124 Calcium Dobesilate 108 daratumumab 95 fludarabine phosphate 69 carfilzomib 69 pomalidomide 68 Peripheral Blood Stem Cell Transplantation 64 Filgrastim 56 Thalidomide 55 Busulfan 53 Mycophenolic Acid 52 Tacrolimus 45 Granulocyte Colony-Stimulating Factor 45 ixazomib 43 fludarabine 42 Whole-Body Irradiation 40 Cyclosporine 35 Etoposide 33 dexamethasone acetate 31 Antilymphocyte Serum 31 isatuximab 29 dexamethasone 21-phosphate 26 Prednisone 26 elotuzumab 25 Biopsy 25 auricularum 24

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Multiple Myeloma × IPH-2101 × Clear all

NCT00999830 2016-03-24

REMYKIR

Innate Pharma

Phase 2 Completed

27 enrolled 10 charts

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡